Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! 

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals. These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth. Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod. Notably, these products could significantly impact patients with acute myocardial infarction and lupus, diseases with significant unmet clinical needs. Viatris believes that executing on its solid business base while pursuing innovation and growth opportunities remains critical to its future success. The company even strengthened its leadership dynamics by appointing Corinne Le Goff as Chief Commercial Officer.